Company Overview of Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of ...
1555 Bayshore Highway
Burlingame, CA 94010
Founded in 2012
Key Executives for Kindred Biosciences, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secretary
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice President of Regulatory Affairs & Quality
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.
Kindred Biosciences, Inc. Key Developments
Kindred Biosciences, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 10 15
Kindred Biosciences, Inc. announced unaudited financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported a net loss of $6.9 million or $0.35 per diluted share, as compared to a net loss of $8.1 million or $0.42 per diluted share for the same period in 2014. Loss from operations was $6.912 million against $8.143 million a year ago.
For the six months, net loss was $13.6 million or $0.69 per diluted share, as compared to a net loss of $14.3 million or $0.80 per diluted share for the same period in 2014. Loss from operations was $13.674 million against $14.320 million a year ago. Net cash used in operating activities for the six months ended June 30, 2015 was approximately $11.4 million.
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 2000 Index
Jun 29 15
Kindred Biosciences, Inc. will be removed from Russell 2000 Index
Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 3000 Index
Jun 29 15
Kindred Biosciences, Inc. will be removed from the Russell 3000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries